
A recent study from the Center for Kidney Disease Research evaluated the prescribing rates of Guideline‐Directed Medical Therapy (GDMT) in patients with diabetes and chronic kidney disease (CKD). The research analyzed data from over 39,000 adults and found that GDMT prescription rates were disappointingly low. ACE inhibitor/ARB had a baseline prescription rate of 70.7% and 40.4% at ≥90 days, SGLT2 inhibitors had 6.0% and 5.0%, while GLP‐1 receptor agonists had 6.8% and 6.3%, respectively. Patients without primary commercial health insurance coverage were less likely to receive GDMT. The study highlights the need for improved prescribing practices for better clinical outcomes.
Like
Save
Share